Latest Conference Coverage

Efficacy of Rimegepant Similar Among Black and African American Adults

Compared with the overall population, outcomes for the coprimary end points of pain freedom and freedom from most bothersome symptom at 2 hours postdose remained superior in rimegepant-treated individuals.

Using a Data-Driven Approach to Assess Clinical Heterogeneity in Migraine: Ali Ezzati, MD

The director of the Neuroinformatics Program at the University of California, Irvine, provided insight on the use of self-organizing maps to cluster different groups of patients with migraine. [WATCH TIME: 4 minutes]

Migraine Treatment Atogepant Outperforms Rimegepant in Matching-Adjusted Indirect Comparison Analysis

Atogepant 60 mg once daily group had significantly larger reductions in mean monthly migraine days across weeks 1-12 and weeks 9-12, with no statistical difference in treatment-emergent adverse events or all-cause discontinuation.

Use of Vaporized Cannabis as a Potential Treatment for Migraine: Nathaniel Schuster, MD

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine discussed promising findings from a placebo-controlled trial assessing cannabis in patients with migraine. [WATCH TIME: 5 minutes]

Behavioral Strategies for Management and Destigmatizing Migraine

Elizabeth K. Seng, PhD, associate professor at Yeshiva University and Albert Einstein College of Medicine, talked about migraine management through the lens of behavioral factors that clinicians can recommend and encourage to their patients.

Defining Research Priorities in Migraine Through Crowdsourcing: Amynah Pradhan, PhD

The associate professor of psychiatry at the University of Illinois at Chicago discussed the various working groups that have been formed to determine the priorities for different topics in migraine at the 2023 AHS Annual Meeting. [WATCH TIME: 5 minutes]

Migraine Related Stigma and its Impact on Patients in Healthcare

Allison Verhaak, PhD, a clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center, discussed focus group and survey data on themes in migraine-related stigma, and the importance of creating a migraine specific stigma scale.

Discontinuation of Peripheral Nerve Blocks and OnabotulinumtoxinA From Adverse Effects in Chronic Migraine

A retrospective cohort study observed no significant difference in the number of patients who discontinued concurrent peripheral nerve blocks and onabotulinumtoxinA, which the authors recognized as a marker of clinical relevance.

Certain Social Determinants of Health Contribute to Increased Rates of Migraine vs Headache Diagnosis

Demographic factors of male sex, non-White race, and having a primary language other than English were associated with a lower odds of being diagnosed with migraine.

Candesartan Shown to be Safe, Effective as Option to Prevent Migraine in Adolescents

Patients on candesartan saw statistically significant reductions in the mean frequency of monthly headache days, including moderate to severe headache days.

Lowest Rates of Discontinuation Observed With Galcanezumab Among Self-Injectable CGRP Monoclonal Antibodies

When comparing galcanezumab, fremanezumab, and erenumab, 3 FDA-approved CGRP medications for preventive migraine, time to switch was lowest for erenumab and similar for galcanezumab and fremanezumab.

Survey Shows Lack of Awareness of Medication-Overuse Headache in Patients with Migraine

Investigators concluded that the increased prevalence of medication-overuse headache might be because of the lack of understanding about the condition in both providers and patients with migraine.

Using a Novel Educational Intervention to Improve Overall Knowledge of Headache: Sara Pavitt, MD

The chief of headache at UT Austin Dell Children’s Hospital provided insight on a new series designed to deliver longitudinal comprehensive pediatric headache education. [WATCH TIME: 3 minutes]

The Impact of Social Participation on Cognitive Function in Patients With Parkinson Disease: Ling Wan-Albert, OTD, OTR/L

The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]

Kinetic Oscillation Stimulation Significantly Reduces Monthly Headache Days in Chronic Migraine

Findings from a subgroup analysis investigating kinetic oscillation stimulation showed that the treatment potential might be an effective and safe option for preventing chronic migraine.

Emerging Therapies in Movement Disorders and Chronic Care Management for Parkinson Disease: Safia Abdillahi, ACNP-BC, DNP

The nurse practitioner in the movement disorder division at Georgetown University Hospital discussed differences in available therapies for movement disorders versus multiple sclerosis and using a chronic care management model in Parkinson disease. [WATCH TIME: 5 minutes]

Contraindicated Medication Use Significantly Impacts Length of Hospitalization in Parkinson Disease

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.

The Rising Prevalence and Behavioral Implications of Dementia in Parkinson Disease: Nahid Mohammadzadeh, MD

At AMTRD 2023, the graduate research assistant at Brown University talked about the prevalence of rapidly progressive dementia and cognition fluctuation in Parkinson disease as well as the effects of treatments for the condition. [WATCH TIME: 5 minutes]

NeuroVoices: Karin Johnson, MD, FAASM, on Advocating for Later School Start Times

The professor of neurology at UMass Chan School of Medicine provided perspective on the benefits of pushing back school start times based on what research has shown.

Filling a Therapeutic Need in Parkinson Disease: Flexibility With IPX203

Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida, provided insight on the therapeutic potential of IPX203, and why it adds flexibility to the treatment of Parkinson disease.

A Multifaceted Approach to Understanding ON and OFF Periods in Parkinson Disease: Salima Brillman, MD

At AMTRD 2023, the movement disorder neurologist at the Parkinson’s Disease and Movement Disorder Center of Silicon Valley talked about the current care landscape for Parkinson disease and improving on-time for patients experiencing OFF periods. [WATCH TIME: 5 minutes]

Advanced Practice Providers Recognize and Consider the Impact of On-Demand Therapy in Parkinson Disease

In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.

Importance of Education, Clinical Examination Before Deep Brain Stimulation: Nasrin Esnaashari, CNS, NPC, DNP

The nurse practitioner at the University of Southern California Keck Medical School provided insight on steps before deep brain stimulation and how they can impact outcomes for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Clinical Improvements in Cataplexy Seen Through Mazindol Extended-Release Treatment

In a secondary analysis of a double-blind trial, mazindol extended-release outperformed placebo on clinician and patient scales of cataplexy severity and excessive daytime sleepiness.

Increasing Utilization of Deep Brain Stimulation in Clinical Practice: Fiona Gupta, MD

The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center shed some light on the use of DBS in the clinic and how it has evolved as a therapeutic option for patients with Parkinson disease. [WATCH TIME: 2 minutes]

Cognitive Behavioral Therapy and Mindfulness-Based Therapy for Fatigue in MS: Anthony Feinstein, MPhil, PhD, FRCP

At CMSC 2023, the professor of psychiatry at the University of Toronto talked about cognitive behavioral therapy and mindfulness-based therapy that shows promise in alleviating fatigue in multiple sclerosis, offering potential treatment options. [WATCH TIME: 5 minutes]

The Launch of AMDAPP and Goals of the Organization: Kelly Papesh, DNP-C, MSN

The executive director of the newly launched Association of Movement Disorder Advanced Practice Providers provided an overview of the organization and what it can offer to APPs. [WATCH TIME: 4 minutes]

BTK Inhibitors in the Management of Relapse and Progressive MS: Amit Bar-Or, MD, FRCPC, FAAN, FANA

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

Care Access Challenges in Parkinson Disease and Movement Disorders: Fiona Gupta, MD

The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center spoke about the challenges with access to care in movement disorders. [WATCH TIME: 2 minutes]

Findings Reveal Protective, Risk Factors Associated With Insomnia in Adults

Over a 5-year period in a study, both insomnia protective and risk factors in adults were observed as significantly associated with the sleep disorder, offering valuable insights for prevention strategies.